These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36150356)

  • 21. Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing.
    Winstanley EL; Zhang Y; Mashni R; Schnee S; Penm J; Boone J; McNamee C; MacKinnon NJ
    Drug Alcohol Depend; 2018 Jul; 188():169-174. PubMed ID: 29778769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.
    Gunadi C; Shi Y
    BMC Public Health; 2023 Jul; 23(1):1326. PubMed ID: 37434122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescription drug monitoring program use and utility by Washington State pharmacists: A mixed-methods study.
    Pett RG; Mancl L; Revere D; Stergachis A
    J Am Pharm Assoc (2003); 2020; 60(1):57-65. PubMed ID: 31753615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.
    Smith N; Martins SS; Kim J; Rivera-Aguirre A; Fink DS; Castillo-Carniglia A; Henry SG; Mooney SJ; Marshall BDL; Davis C; Cerdá M
    Addiction; 2019 Feb; 114(2):248-258. PubMed ID: 30207015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline.
    Haines S; Lam A; Savic M; Carter A
    Int J Drug Policy; 2022 Nov; 109():103847. PubMed ID: 36067724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impacts of prescription drug monitoring program policy changes and county opioid safety coalitions on prescribing and overdose outcomes in California, 2015-2018.
    Henry SG; Shev AB; Crow D; Stewart SL; Wintemute GJ; Fenlon C; Wirtz SJ
    Prev Med; 2021 Dec; 153():106861. PubMed ID: 34687731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
    Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists.
    Alley L; Novak K; Havlin T; Irwin AN; Carson J; Johnston K; O'Kane N; Hartung DM
    Res Social Adm Pharm; 2020 Oct; 16(10):1422-1430. PubMed ID: 31953112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy and validity of reported opioid prescription days' supply.
    Miracle DK; Slavova S; Brown JR; Dasgupta N; Harris S; Freeman PR
    Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1253-1261. PubMed ID: 36053913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis.
    Picco L; Lam T; Haines S; Nielsen S
    Drug Alcohol Depend; 2021 Nov; 228():109090. PubMed ID: 34600255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Did prescribing laws disproportionately affect opioid dispensing to Black patients?
    Townsend TN; Bohnert ASB; Lagisetty P; Haffajee RL
    Health Serv Res; 2022 Jun; 57(3):482-496. PubMed ID: 35243639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-care practitioner use of prescription drug monitoring programs in clinical practice in Australia: A qualitative study.
    Hoppe D; George Liu C; Khalil H
    Drug Alcohol Rev; 2023 Nov; 42(7):1647-1657. PubMed ID: 37402606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Educating Pharmacists on a Prescription Drug Monitoring Program.
    Fleming ML; Phan Y; Ferries EA; Hatfield MD
    J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review.
    Thakur T; Frey M; Chewning B
    J Am Pharm Assoc (2003); 2020; 60(1):178-194. PubMed ID: 31371179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstate data sharing of prescription drug monitoring programs and associated opioid prescriptions among patients with non-cancer chronic pain.
    Lin HC; Wang Z; Simoni-Wastila L; Boyd C; Buu A
    Prev Med; 2019 Jan; 118():59-65. PubMed ID: 30316875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.